This product is an enolic acid nonsteroidal anti-inflammatory drug (NSAID) with strong anti-inflammatory, analgesic and antipyretic effects. It can inhibit the synthesis of prostaglandins and selectively inhibit cyclooxygenase-2 (COX-2), making it safer than other NSAIDs.

In accordance with the requirements of the "Non-clinical Drug Research Management Standards", multiple experiments were conducted on mice, guinea pigs and cats. The results showed that there were no abnormal toxic reactions, the requirements for antihypertensive substances were met, there were no allergic reactions and deaths; no abnormal reactions were observed when the maximum dosage in mice was greater than 100ml/kg.

(1) According to the requirements of the "Non-clinical Drug Research Management Standards" and the relevant guidelines for preclinical research of new drugs in the country, the product was injected into mice at a dose of 0.8 ml/mouse. No abnormal toxic reaction or death was observed within 48 hours after injection. The abnormal toxicity test results for mice were qualified. (2) According to the method requirements for the antihypertensive substance test in the appendix of the "Pharmacopoeia of the People's Republic of China", this product was tested for antihypertensive substances in cats, and the results met the antihypertensive substance requirements specified in the Pharmacopoeia. (3) According to the requirements of the "Non-clinical Drug Research Management Standards" and the relevant guidelines for preclinical research of new drugs in China, the product was injected intraperitoneally into healthy white Hautley guinea pigs, 0.5 ml per guinea pig, once every other day, for 3 consecutive times for sensitization. The results showed that the product had no effect on the activity, food intake, and drinking water of guinea pigs, and had no significant effect on the weight gain of guinea pigs. No abnormal reactions occurred during the test, and no guinea pigs died. The incidence rate and mortality rate of allergic reactions were both 0.4) According to the requirements of the "Non-clinical Drug Research Management Standards" and the relevant guidelines for preclinical research of new drugs in China, the product was injected intravenously into healthy clean-grade ICR mice at a dose of 100 ml/kg. After administration, no abnormal reactions were observed in male and female mice, and no animal deaths were caused. The maximum dosage for mice is greater than 100 ml/kg.

(1) According to the requirements of the "Non-clinical Drug Research Management Standards" and the relevant guidelines for preclinical research of new drugs in the country, the product was injected into mice at a dose of 0.8 ml/mouse. No abnormal toxic reaction or death was observed within 48 hours after injection. The abnormal toxicity test results for mice were qualified. (2) According to the method requirements for the antihypertensive substance test in the appendix of the "Pharmacopoeia of the People's Republic of China", this product was tested for antihypertensive substances in cats, and the results met the antihypertensive substance requirements specified in the Pharmacopoeia. (3) According to the requirements of the "Non-clinical Drug Research Management Standards" and the relevant guidelines for preclinical research of new drugs in China, the product was injected intraperitoneally into healthy white Hautley guinea pigs, 0.5 ml per guinea pig, once every other day, for 3 consecutive times for sensitization. The results showed that the product had no effect on the activity, food intake, and drinking water of guinea pigs, and had no significant effect on the weight gain of guinea pigs. No abnormal reactions occurred during the test, and no guinea pigs died. The incidence rate and mortality rate of allergic reactions were both 0.4) According to the requirements of the "Non-clinical Drug Research Management Standards" and the relevant guidelines for preclinical research of new drugs in China, the product was injected intravenously into healthy clean-grade ICR mice at a dose of 100 ml/kg. After administration, no abnormal reactions were observed in male and female mice, and no animal deaths were caused. The maximum dosage for mice is greater than 100 ml/kg.

Reduce fever and prevent febrile convulsions

Heat-clearing and detoxifying, antibacterial and anti-inflammatory

Heat-clearing and detoxifying, antibacterial and anti-inflammatory

Heat-clearing and detoxifying, antibacterial and anti-inflammatory

Calming the nerves and calming the nerves

Calming the nerves and calming the nerves

Detoxification and Heat

Heat-clearing and detoxifying, antibacterial and anti-inflammatory

Reduce swelling and relieve pain

Reduce fever and prevent febrile convulsions

Reduce fever and prevent febrile convulsions

It has special effects on the following bacteria: Staphylococcus (Staphylococcus aureus, Staphylococcus epidermidis and penicillin-resistant bacteria), Streptococcus (Group A hemolytic streptococcus, non-hemolytic streptococcus and Streptococcus pneumoniae), Pseudomonas aeruginosa, Escherichia coli, Klebsiella pneumoniae, Escherichia coli, Proteus mirabilis (indole-negative) and indole-positive Proteus, Haemophilus influenzae and Haemophilus conjunctivitis, Moraxella conjunctivitis, Acinetobacter calcoaceticus (Herellea vaginacola), Neisseria. Bacteria resistant to gentamicin are still sensitive to tobramycin. No bacteria resistant to tobramycin have been found so far, but long-term use may lead to bacterial resistance.